Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 20
Filter
1.
Hypertension ; 60(3): 730-40, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22777933

ABSTRACT

A newly produced murine recombinant angiotensin (Ang)-converting enzyme 2 (ACE2) was characterized in vivo and in vitro. The effects of available ACE2 inhibitors (MLN-4760 and 2 conformational variants of DX600, linear and cyclic) were also examined. When murine ACE2 was given to mice for 4 weeks, a marked increase in serum ACE2 activity was sustainable. In acute studies, mouse ACE2 (1 mg/kg) obliterated hypertension induced by Ang II infusion by rapidly decreasing plasma Ang II. These effects were blocked by MLN-4760 but not by either form of DX600. In vitro, conversion from Ang II to Ang-(1-7) by mouse ACE2 was blocked by MLN-4760 (10(-6) m) but not by either form of DX600 (10(-5) m). Quantitative analysis of multiple Ang peptides in plasma ex vivo revealed formation of Ang-(1-9) from Ang I by human but not by mouse ACE2. Both human and mouse ACE2 led to the dissipation of Ang II with formation of Ang (1-7). By contrast, mouse ACE2-driven Ang-(1-7) formation from Ang II was blocked by MLN-4760 but not by either linear or cyclic DX600. In conclusion, sustained elevations in serum ACE2 activity can be accomplished with murine ACE2 administration, thereby providing a strategy for ACE2 amplification in chronic studies using rodent models of hypertension and cardiovascular disease. Human but not mouse ACE2 degrades Ang I to form Ang-(1-9). There are also species differences regarding rodent and human ACE2 inhibition by known inhibitors such that MLN-4760 inhibits both human and mouse ACE2, whereas DX600 only blocks human ACE2 activity.


Subject(s)
Angiotensin II/metabolism , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Hypertension/metabolism , Peptidyl-Dipeptidase A/metabolism , Peptidyl-Dipeptidase A/pharmacology , Angiotensin I/metabolism , Angiotensin-Converting Enzyme 2 , Animals , Blood Pressure/drug effects , Disease Models, Animal , Humans , Hydrolysis , Hypertension/physiopathology , Imidazoles/pharmacology , In Vitro Techniques , Kidney/metabolism , Leucine/analogs & derivatives , Leucine/pharmacology , Male , Mice , Mice, Inbred C57BL , Peptide Fragments/metabolism , Peptides/pharmacology , Peptidyl-Dipeptidase A/drug effects , Recombinant Proteins/pharmacology
2.
Hypertension ; 55(1): 90-8, 2010 Jan.
Article in English | MEDLINE | ID: mdl-19948988

ABSTRACT

Angiotensin (Ang)-converting enzyme 2 (ACE2) cleaves Ang II to form Ang-(1-7). Here we examined whether soluble human recombinant ACE2 (rACE2) can efficiently lower Ang II and increase Ang-(1-7) and whether rACE2 can prevent hypertension caused by Ang II infusion as a result of systemic versus local mechanisms of ACE2 activity amplification. rACE2 was infused via osmotic minipumps for 3 days in conscious mice or acutely in anesthetized mice. rACE2 caused a dose-dependent increase in serum ACE2 activity but had no effect on kidney or cardiac ACE2 activity. After Ang II infusion (40 pmol/min), rACE2 (1 mg/kg per day) resulted in normalization of systolic blood pressure and plasma Ang II. In acute studies, rACE2 (1 mg/kg) prevented the rapid hypertensive effect of Ang II (0.2 mg/kg), and this was associated with both a decrease in Ang II and an increase in Ang-(1-7) in plasma. Moreover, during infusion of Ang II, the effect of rACE2 on blood pressure was unaffected by a specific Ang-(1-7) receptor blocker, A779 (0.2 mg/kg), and infusing supraphysiologic levels of Ang-(1-7) (0.2 mg/kg) had no effect on blood pressure. We conclude that, during Ang II infusion, rACE2 effectively degrades Ang II and, in the process, normalizes blood pressure. The mechanism of rACE2 action results from an increase in systemic, not tissue, ACE2 activity and the lowering of plasma Ang II rather than the attendant increase in Ang-(1-7). Increasing ACE2 activity may provide a new therapeutic target in states of Ang II overactivity by enhancing its degradation, an approach that differs from the current focus on blocking Ang II formation and action.


Subject(s)
Angiotensin II/metabolism , Hypertension/metabolism , Peptidyl-Dipeptidase A/metabolism , Recombinant Proteins/metabolism , Anesthesia , Angiotensin I/blood , Angiotensin I/metabolism , Angiotensin II/administration & dosage , Angiotensin II/analogs & derivatives , Angiotensin II/blood , Angiotensin II Type 1 Receptor Blockers/antagonists & inhibitors , Angiotensin-Converting Enzyme 2 , Animals , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Humans , Hypertension/chemically induced , Hypertension/prevention & control , Infusion Pumps , Kidney/drug effects , Kidney/metabolism , Male , Mice , Mice, Inbred C57BL , Mice, Knockout , Peptide Fragments/administration & dosage , Peptide Fragments/blood , Peptide Fragments/metabolism , Peptidyl-Dipeptidase A/administration & dosage , Peptidyl-Dipeptidase A/genetics , Recombinant Proteins/administration & dosage
3.
J Nephrol ; 22(5): 647-53, 2009.
Article in English | MEDLINE | ID: mdl-19809998

ABSTRACT

BACKGROUND: Vascular calcification is a serious complication of chronic kidney disease. Acid-base balance is a relevant, albeit somewhat forgotten factor in the regulation of calcium deposition. Hemodialysis patients undergo repeated episodes of alkaline loading from the dialysate, resulting in prolonged alkalinization. We have hypothesized that extracellular alkalinization may promote vascular calcification. METHODS: Primary cultures of vascular smooth muscle cells were induced to calcify by the phosphate donor beta-glycerophosphate, in the presence of normal or uremic sera from hemodialysis patients and at different pH conditions. The influence of sodium bicarbonate supplementation for 2 months on aorta calcification was studied in 5/6 nephrectomized uremic rats. RESULTS: Uremic serum increased vascular smooth muscle cell calcification (twofold over nonuremic human serum at day 12, p<0.001). Alkalinization of the extracellular medium also increased vascular smooth muscle cell calcification. Increasing the extracellular pH from 7.42 to 7.53 resulted in a 2.5-fold increase in calcium accumulation at day 12 (p<0.05). In vivo, arterial calcification was significantly higher in alkalinized uremic animals (aorta calcification index, uremic + sodium bicarbonate, 164 +/- 57 units, vs. uremic + vehicle, 56 +/- 14 units; p<0.01). CONCLUSIONS: Alkalinization increases vascular calcification in cultured cells and uremic rats. These data may be used to optimize dialysate composition and the degree of alkalinization in calcification-prone individuals with advanced renal disease.


Subject(s)
Bicarbonates/metabolism , Calcium/metabolism , Muscle, Smooth, Vascular/metabolism , Uremia/metabolism , Acid-Base Equilibrium , Animals , Aorta/cytology , Aorta/metabolism , Bicarbonates/pharmacology , Cattle , Cells, Cultured , Disease Models, Animal , Humans , Hydrogen-Ion Concentration , Male , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Nephrectomy/adverse effects , Rats , Rats, Wistar , Uremia/etiology
4.
Kidney Int ; 75(2): 227-34, 2009 Jan.
Article in English | MEDLINE | ID: mdl-18818682

ABSTRACT

Cyclosporin A is an immunosuppressant drug widely used in solid organ transplantation, but it has nephrotoxic properties that promote oxidative stress. The JAK2/STAT pathway has been implicated in both cell protection and cell injury; therefore, we determined a role of JAK2 in oxidative stress-mediated renal cell injury using pathophysiologically relevant oxidative challenges. The AG490 JAK2 inhibitor and overexpression of a dominant negative JAK2 protein protected endothelial and renal epithelial cells in culture against peroxide, superoxide anion and cyclosporin A induced cell death while reducing intracellular oxidation in cells challenged with peroxide and cyclosporin A. The decrease in Bcl2 expression and caspase 3 activation, induced by oxidative stress, was prevented by AG490. In mouse models of ischemia/reperfusion and cyclosporin A nephrotoxicity, AG490 decreased peritubular capillary and tubular cell injury. Our study shows that JAK2 inhibition is a promising renoprotective strategy defending endothelial and tubular cells from cyclosporin A- and oxidative stress-induced death.


Subject(s)
Cyclosporine/toxicity , Endothelial Cells/metabolism , Epithelial Cells/metabolism , Janus Kinase 2/antagonists & inhibitors , Kidney/cytology , Oxidative Stress/drug effects , Tyrphostins/pharmacology , Animals , Endothelial Cells/drug effects , Epithelial Cells/drug effects , Janus Kinase 2/physiology , Mice , Protective Agents/pharmacology , Reperfusion Injury/drug therapy , Reperfusion Injury/prevention & control
5.
Curr Hypertens Rep ; 10(1): 70-7, 2008 Feb.
Article in English | MEDLINE | ID: mdl-18367030

ABSTRACT

The discovery of angiotensin-converting enzyme (ACE) 2 adds a new level of complexity to the understanding of the renin-angiotensin system. The high catalytic efficiency of ACE2 for the generation of angiotensin (ANG)-1-7 from ANG II suggests an important role of ACE2 in preventing ANG II accumulation, while at the same time enhancing ANG-1-7 formation. ACE and ACE2 may have counterbalancing functions and a regulatory role in fine-tuning the rate at which ANG peptides are formed and degraded. By counterregulating the actions of ACE on ANG II formation, ACE2 may play a role in maintaining a balanced status of the renin-angiotensin system. This review focuses on the function of ACE2 and its possible roles in kidney disease and hypertension. Studies using models of ACE2 ablation and the pharmacologic administration of an ACE2 inhibitor suggest that decreased ACE2 activity alone or in combination with increased ACE activity may play a role in both diseases.


Subject(s)
Hypertension/metabolism , Kidney Diseases/metabolism , Peptidyl-Dipeptidase A/metabolism , Angiotensin I , Angiotensin II/metabolism , Angiotensin-Converting Enzyme 2 , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Biological Assay , Humans , Hypertension/physiopathology , Kidney/physiopathology , Kidney Diseases/physiopathology , Renin-Angiotensin System
6.
J Biol Chem ; 283(17): 11435-44, 2008 Apr 25.
Article in English | MEDLINE | ID: mdl-18305118

ABSTRACT

Transcriptional regulation of vascular endothelial growth factor (VEGF) is critically dependent on hypoxia-inducible factor 1 (HIF-1). However, not only hypoxia, but selected growth factors can induce HIF-1. High levels of both VEGF and HIF-1 coexist in certain conditions, e.g. tumors. Nonetheless, the possibility that the stimulatory relationship between HIF-1 and VEGF may be bi-directional has not been addressed up to date. The present study in endothelial cells analyzed whether HIF-1 is regulated by a product of its own transcriptionally activated genes, namely, VEGF. As a main finding, VEGF-A(165) induced the increase of HIF-1alpha mRNA and HIF-1alpha protein and nuclear translocation. Autologous endothelial cell VEGF mRNA and protein were also increased upon exposure to exogenous VEGF. The signaling implication of reactive oxygen species was examined by comparison with H(2)O(2) and hypoxanthine/xanthine oxidase and by the superoxide dismutase mimetic, MnTMPyP, the Rac1-NAD(P)H oxidase complex inhibitor, apocynin, transfection of a dominant negative Rac1 mutant, and transfection of a p67phox antisense oligonucleotide. Superoxide anion, largely dependent on Rac1-NAD(P)H oxidase complex activity, was the critical signaling element. The transductional functionality of the pathway was confirmed by means of a reporter gene flanked by a transcription site-related VEGF sequence and by quantitative PCR. In summary, the present results reveal a previously undescribed action of VEGF on the expression of its own transcription factor, HIF-1, and on VEGF itself. This effect is principally mediated by superoxide anion, therefore identifying a new, potentially relevant role of reactive oxygen species in VEGF signaling.


Subject(s)
Gene Expression Regulation , Hypoxia-Inducible Factor 1, alpha Subunit/metabolism , Vascular Endothelial Growth Factor A/metabolism , Animals , Cattle , Cytoplasm/metabolism , Humans , Hydrogen Peroxide/pharmacology , Hypoxanthine/metabolism , Models, Biological , Mutation , Reactive Oxygen Species , Superoxide Dismutase/metabolism , Superoxides/metabolism , Xanthine Oxidase/metabolism , rac1 GTP-Binding Protein/genetics , rac1 GTP-Binding Protein/metabolism
7.
Am J Physiol Cell Physiol ; 292(3): C1123-31, 2007 Mar.
Article in English | MEDLINE | ID: mdl-17035297

ABSTRACT

Inhibition of the JAK2/STAT pathway has been implicated recently in cytoprotective mechanisms in both vascular smooth muscle cells and astrocytes. The advent of JAK2-specific inhibitors provides a practical tool for the study of this pathway in different cellular types. An interest in finding methods to improve endothelial cell (EC) resistance to injury led us to examine the effect of JAK2/STAT inhibition on EC protection. Furthermore, the signaling pathways involved in JAK2/STAT inhibition-related actions were examined. Our results reveal, for the first time, that blockade of JAK2 with the tyrosine kinase inhibitor AG490 strongly protects cultured EC against cell detachment-dependent death and serum deprivation and increases reseeding efficiency. Confirmation of the specificity of the effects of JAK2 inhibition was attained by finding protective effects on transfection with a dominant negative JAK2. Furthermore, AG490 blocked serum deprivation-induced phosphorylation of JAK2. In terms of mechanism, treatment with AG490 induces several relevant responses, both in monolayer and detached cells. These mechanisms include the following: 1) Increase and nuclear translocation of the active, dephosphorylated form of beta-catenin. In functional terms, this translocation is transcriptionally active, and its protective effect is further supported by the stimulation of EC cytoprotection by transfectionally induced excess of beta-catenin. 2) Increase of platelet endothelial cell adhesion molecule (PECAM)/CD31 levels. 3) Increase in total and phosphorylated AKT. 4) Increase in phosphorylated glycogen synthase kinase (GSK)3alpha/beta. The present findings imply potential practical applications of JAK2 inhibition on EC. These applications affect not only EC in the monolayer but also circulating detached cells and involve mechanistic interactions not previously described.


Subject(s)
Endothelial Cells/cytology , Endothelial Cells/metabolism , Janus Kinase 2/antagonists & inhibitors , Janus Kinase 2/metabolism , Signal Transduction/physiology , Tyrphostins/administration & dosage , Animals , Cattle , Cell Survival/drug effects , Cells, Cultured , Cytoprotection/drug effects , Cytoprotection/physiology , Dose-Response Relationship, Drug , Humans , Signal Transduction/drug effects
8.
Am J Physiol Heart Circ Physiol ; 291(3): H1395-401, 2006 Sep.
Article in English | MEDLINE | ID: mdl-16899768

ABSTRACT

The defense mechanisms of endothelial cells (EC) against reactive oxygen species (ROS) are insufficiently characterized. We have addressed the hypothesis that vascular endothelial growth factor (VEGF) and its receptors are relevant elements in this response. Cell viability, VEGF and VEGF receptor (VEGFR1 and VEGFR2) expression, and transcription factor activation were studied on transient exposure of monolayer EC to H2O2. Wild-type and mutant inhibitors of kappaBalpha (IkappaBalpha) constructions were used to further assess the role of NF-kappaB in the induction of VEGFR2 expression. A concentration of H2O2>or=60 microM elicited clear-cut damaging effects on EC, whereas lower concentrations (2-4 microM) were cytoprotective. The cytoprotective effect was shifted to an EC-damaging pattern by means of specific VEGF blockade, therefore revealing a major role of autologous VEGF. Exposure to H2O2 increased VEGF and VEGFR2 mRNA and protein in EC, without affecting VEGFR1 expression. Also, H2O2 challenge was accompanied by increased NF-kappaB, activator protein-1, and specific protein-1 nuclear binding. A role of NF-kappaB as the mediator of the H2O2 induction of VEGFR2 mRNA expression was supported by inhibition by the ROS scavenger pyrrolidine dithiocarbamate and by the blocking effect of transfected IkappaBalpha. Exposure to exogenous VEGF also increased VEGFR2 and induced NF-kappaB in EC. In summary, autologous VEGF is instrumental for EC protection induced by low concentrations of ROS. ROS induce expression not only of VEGF but also of VEGFR2. VEGFR2 increase by ROS is mainly driven through a NF-kappaB-dependent pathway.


Subject(s)
Endothelium, Vascular/physiology , Hydrogen Peroxide/pharmacology , Reactive Oxygen Species/pharmacology , Vascular Endothelial Growth Factor A/metabolism , Vascular Endothelial Growth Factor Receptor-2/metabolism , Animals , Antioxidants/pharmacology , Cattle , Cell Survival/drug effects , Cell Survival/physiology , Cells, Cultured , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Gene Expression Regulation/drug effects , Gene Expression Regulation/physiology , I-kappa B Proteins/pharmacology , NF-KappaB Inhibitor alpha , NF-kappa B/physiology , Oxidative Stress/physiology , Pyrrolidines/pharmacology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Thiocarbamates/pharmacology , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor Receptor-1/genetics , Vascular Endothelial Growth Factor Receptor-1/metabolism , Vascular Endothelial Growth Factor Receptor-2/genetics
9.
Medicina (B Aires) ; 66(2): 155-64, 2006.
Article in Spanish | MEDLINE | ID: mdl-16715769

ABSTRACT

New, critically important data have been recently generated about the response to hypoxia. This response can be schematized in three main systems or functions, ie, detectional or oxygen sensing, regulatory, which controls gene expression and effector. The principal organizer of the regulatory branch is a specific transcription factor, the hypoxia-inducible factor 1 (HIF-1). In the presence of oxygen, the alpha subunit of HIF-1 (HIF-1alpha) is modified by hydroxylases, that represent the central point of the oxygen sensing mechanism. This type of hydroxylation induces HIF-1alpha catabolism by the proteosome. On the contrary, in hypoxia, or in the presence of certain growth factors that increase HIF-1alpha synthesis, HIF-1alpha translocates to the nucleus, where it binds HIF-1beta, and thence acts on transcription of genes carrying hypoxia responsive elements (HRE) on their promoters. These genes regulate the synthesis of an ample series of proteins, which span from respiratory enzymes and transporters to hormones regulating circulation and erythropoiesis. The role of HIF-1alpha is not restricted to the mere induction of adaptation to decreased oxygen: instead, it significantly participates in cell repairing mechanisms. A simple list of some of the stimulatory or inhibitory alterations of pathophysiological importance involving the HIF-1 system, would include: chronic lung disease, smoking adaptation, anemia/hemorrhage, ischemia/reperfusion, growth, vascularization and cell resistance of tumors, preeclampsia and intrauterine growth retardation, retinal hyper o hypovascularization, drug intoxications, bowel inflammatory disease and wound repair. This list illustrates by itself the importance of the mechanism herein reviewed.


Subject(s)
Gene Expression Regulation/physiology , Hypoxia-Inducible Factor 1/physiology , Hypoxia/genetics , Heart Diseases/genetics , Heart Diseases/physiopathology , Humans , Hypoxia/physiopathology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/physiopathology
10.
Medicina (B.Aires) ; 66(2): 155-164, 2006. ilus
Article in Spanish | LILACS | ID: lil-440406

ABSTRACT

La respuesta hipóxica, sobre la que se dispone de nuevos datos críticamente importantes, puede esquematizarse en tres sistemas, vg. de detección o sensor de oxígeno, de regulación, que controla la expresión génica y efector. El elemento principal de organización del sistema regulador es un factor de transcripción específico, el factor inducible por hipoxia 1 (HIF-1). En presencia de oxígeno, la subunidad α del HIF-1 (HIF-1α) se modifica por las hidroxilasas, que constituyen el punto central del mecanismo sensor, induciendo su catabolismo por el proteosoma. Por el contrario, en hipoxia, o en presencia de algunos factores de crecimiento que incrementan su síntesis, el HIF-1α se transloca al núcleo, donde, unido al HIF-1β, actúa como factor transcripcional de genes con elementos de respuesta hipóxica (HRE) en su promotor. Estos regulan lasíntesis de una amplia serie de proteínas, que abarcan desde enzimas respiratorias y transportadores hasta hormonas involucradas en la regulación a escala del organismo de la circulación y la eritropoyesis. El papel del HIF-1 no se restringe a la mera inducción de una respuesta adaptativa a la falta de oxígeno, sino que participa significativamente en los mecanismos de reparación celular. Una simple lista de algunas alteraciones de importância fisiopatológica, tanto estimulatorias como inhibitorias, que involucran al sistema de HIF-1, incluiría: enfermedad pulmonar crónica, adaptación al tabaco/humo, anemia/hemorragia, isquemia/reperfusión, crecimiento, vascularización y resistencia celular de los tumores, preeclampsia y crecimiento intrauterino retardado, hiper o hipovascularización retiniana, sobredosis de fármacos, enfermedad inflamatoria intestinal y curación de heridas. Esta sola enumeración ilustra la importancia de este mecanismo. .


New, critically important data have been recently generated about the response to hypoxia. This response can be schematized in three main systems or functions, ie, detectional or oxygen sensing, regulatory, which controls gene expression and effector. The principal organizer of the regulatory branch is a specific transcription factor, the hypoxia-inducible factor 1 (HIF-1). In the presence of oxygen, the α subunit of HIF-1 (HIF-1α) is modified by hydroxylases, that represent the central point of the oxygen sensing mechanism. This type of hydroxylation induces HIF-1α catabolism by the proteosome. On the contrary, in hypoxia, or in the presence of certain growth factors that increase HIF-1α synthesis, HIF-1α translocates to the nucleus, where it binds HIF-1β, and thence acts on transcription of genes carrying hypoxia responsive elements (HRE) on their promoters. These genes regulate the synthesis of an ample series of proteins, which span from respiratory enzymes and transporters to hormones regulating circulation and erythropoiesis. The role of HIF-1α is not restricted to the mere induction of adaptation to decreased oxygen: instead, it significantly participates in cell repairing mechanisms. A simple list of some of the stimulatory or inhibitory alterations of pathophysiological importance involving the HIF-1 system, would include: chronic lung disease, smoking adaptation, anemia/hemorrhage, ischemia/reperfusion, growth, vascularization and cell resistance of tumors, preeclampsia and intrauterine growth retardation, retinal hyper ohypovascularization, drug intoxications, bowel inflammatory disease and wound repair. This list illustrates by itself the importance of the mechanism herein reviewed.


Subject(s)
Humans , Hypoxia/genetics , Gene Expression Regulation/physiology , Hypoxia-Inducible Factor 1/physiology , Hypoxia/physiopathology , Heart Diseases/genetics , Heart Diseases/physiopathology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/physiopathology
11.
Medicina (B.Aires) ; 66(2): 155-164, 2006. ilus
Article in Spanish | BINACIS | ID: bin-123443

ABSTRACT

La respuesta hipóxica, sobre la que se dispone de nuevos datos críticamente importantes, puede esquematizarse en tres sistemas, vg. de detección o sensor de oxígeno, de regulación, que controla la expresión génica y efector. El elemento principal de organización del sistema regulador es un factor de transcripción específico, el factor inducible por hipoxia 1 (HIF-1). En presencia de oxígeno, la subunidad α del HIF-1 (HIF-1α) se modifica por las hidroxilasas, que constituyen el punto central del mecanismo sensor, induciendo su catabolismo por el proteosoma. Por el contrario, en hipoxia, o en presencia de algunos factores de crecimiento que incrementan su síntesis, el HIF-1α se transloca al núcleo, donde, unido al HIF-1β, actúa como factor transcripcional de genes con elementos de respuesta hipóxica (HRE) en su promotor. Estos regulan lasíntesis de una amplia serie de proteínas, que abarcan desde enzimas respiratorias y transportadores hasta hormonas involucradas en la regulación a escala del organismo de la circulación y la eritropoyesis. El papel del HIF-1 no se restringe a la mera inducción de una respuesta adaptativa a la falta de oxígeno, sino que participa significativamente en los mecanismos de reparación celular. Una simple lista de algunas alteraciones de importÔncia fisiopatológica, tanto estimulatorias como inhibitorias, que involucran al sistema de HIF-1, incluiría: enfermedad pulmonar crónica, adaptación al tabaco/humo, anemia/hemorragia, isquemia/reperfusión, crecimiento, vascularización y resistencia celular de los tumores, preeclampsia y crecimiento intrauterino retardado, hiper o hipovascularización retiniana, sobredosis de fármacos, enfermedad inflamatoria intestinal y curación de heridas. Esta sola enumeración ilustra la importancia de este mecanismo. (AU).


New, critically important data have been recently generated about the response to hypoxia. This response can be schematized in three main systems or functions, ie, detectional or oxygen sensing, regulatory, which controls gene expression and effector. The principal organizer of the regulatory branch is a specific transcription factor, the hypoxia-inducible factor 1 (HIF-1). In the presence of oxygen, the α subunit of HIF-1 (HIF-1α) is modified by hydroxylases, that represent the central point of the oxygen sensing mechanism. This type of hydroxylation induces HIF-1α catabolism by the proteosome. On the contrary, in hypoxia, or in the presence of certain growth factors that increase HIF-1α synthesis, HIF-1α translocates to the nucleus, where it binds HIF-1β, and thence acts on transcription of genes carrying hypoxia responsive elements (HRE) on their promoters. These genes regulate the synthesis of an ample series of proteins, which span from respiratory enzymes and transporters to hormones regulating circulation and erythropoiesis. The role of HIF-1α is not restricted to the mere induction of adaptation to decreased oxygen: instead, it significantly participates in cell repairing mechanisms. A simple list of some of the stimulatory or inhibitory alterations of pathophysiological importance involving the HIF-1 system, would include: chronic lung disease, smoking adaptation, anemia/hemorrhage, ischemia/reperfusion, growth, vascularization and cell resistance of tumors, preeclampsia and intrauterine growth retardation, retinal hyper ohypovascularization, drug intoxications, bowel inflammatory disease and wound repair. This list illustrates by itself the importance of the mechanism herein reviewed. (AU)


Subject(s)
Humans , Hypoxia/genetics , Gene Expression Regulation/physiology , Hypoxia-Inducible Factor 1/physiology , Hypoxia/physiopathology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Heart Diseases/genetics , Heart Diseases/physiopathology , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/physiopathology
12.
Medicina (B.Aires) ; 66(2): 155-164, 2006. ilus
Article in Spanish | BINACIS | ID: bin-119576

ABSTRACT

La respuesta hipóxica, sobre la que se dispone de nuevos datos críticamente importantes, puede esquematizarse en tres sistemas, vg. de detección o sensor de oxígeno, de regulación, que controla la expresión génica y efector. El elemento principal de organización del sistema regulador es un factor de transcripción específico, el factor inducible por hipoxia 1 (HIF-1). En presencia de oxígeno, la subunidad α del HIF-1 (HIF-1α) se modifica por las hidroxilasas, que constituyen el punto central del mecanismo sensor, induciendo su catabolismo por el proteosoma. Por el contrario, en hipoxia, o en presencia de algunos factores de crecimiento que incrementan su síntesis, el HIF-1α se transloca al núcleo, donde, unido al HIF-1β, actúa como factor transcripcional de genes con elementos de respuesta hipóxica (HRE) en su promotor. Estos regulan lasíntesis de una amplia serie de proteínas, que abarcan desde enzimas respiratorias y transportadores hasta hormonas involucradas en la regulación a escala del organismo de la circulación y la eritropoyesis. El papel del HIF-1 no se restringe a la mera inducción de una respuesta adaptativa a la falta de oxígeno, sino que participa significativamente en los mecanismos de reparación celular. Una simple lista de algunas alteraciones de importÔncia fisiopatológica, tanto estimulatorias como inhibitorias, que involucran al sistema de HIF-1, incluiría: enfermedad pulmonar crónica, adaptación al tabaco/humo, anemia/hemorragia, isquemia/reperfusión, crecimiento, vascularización y resistencia celular de los tumores, preeclampsia y crecimiento intrauterino retardado, hiper o hipovascularización retiniana, sobredosis de fármacos, enfermedad inflamatoria intestinal y curación de heridas. Esta sola enumeración ilustra la importancia de este mecanismo. (AU).


New, critically important data have been recently generated about the response to hypoxia. This response can be schematized in three main systems or functions, ie, detectional or oxygen sensing, regulatory, which controls gene expression and effector. The principal organizer of the regulatory branch is a specific transcription factor, the hypoxia-inducible factor 1 (HIF-1). In the presence of oxygen, the α subunit of HIF-1 (HIF-1α) is modified by hydroxylases, that represent the central point of the oxygen sensing mechanism. This type of hydroxylation induces HIF-1α catabolism by the proteosome. On the contrary, in hypoxia, or in the presence of certain growth factors that increase HIF-1α synthesis, HIF-1α translocates to the nucleus, where it binds HIF-1β, and thence acts on transcription of genes carrying hypoxia responsive elements (HRE) on their promoters. These genes regulate the synthesis of an ample series of proteins, which span from respiratory enzymes and transporters to hormones regulating circulation and erythropoiesis. The role of HIF-1α is not restricted to the mere induction of adaptation to decreased oxygen: instead, it significantly participates in cell repairing mechanisms. A simple list of some of the stimulatory or inhibitory alterations of pathophysiological importance involving the HIF-1 system, would include: chronic lung disease, smoking adaptation, anemia/hemorrhage, ischemia/reperfusion, growth, vascularization and cell resistance of tumors, preeclampsia and intrauterine growth retardation, retinal hyper ohypovascularization, drug intoxications, bowel inflammatory disease and wound repair. This list illustrates by itself the importance of the mechanism herein reviewed. (AU)


Subject(s)
Humans , Hypoxia/genetics , Gene Expression Regulation/physiology , Hypoxia-Inducible Factor 1/physiology , Hypoxia/physiopathology , Hypoxia-Inducible Factor 1, alpha Subunit/physiology , Heart Diseases/genetics , Heart Diseases/physiopathology , Pulmonary Disease, Chronic Obstructive/genetics , Pulmonary Disease, Chronic Obstructive/physiopathology
13.
J Nephrol ; 18(3): 234-42, 2005.
Article in English | MEDLINE | ID: mdl-16013009

ABSTRACT

BACKGROUND: In spite of intensive research, the actual role of heparin in endothelial cell (EC) biology remains incompletely understood. In particular, further insight is needed into the interaction of heparin with the potent heparin-binding angiogenic factor, vascular endothelial growth factor (VEGF). This study aimed to examine the effect of heparin on VEGF-mediated EC responses. METHODS: Confluent bovine aorta EC were treated with high (HMWH) and low molecular weight heparin (LMWH). 3H-Thymidine (3H-Thy) uptake, flow cytometry, 51Cr-release, nitrites accumulation, and cytosolic free Ca2+ ([Ca2+]i), endothelial nitric oxide synthase (eNOS) mRNA expression and tissue factor (TF) concentration were measured. RESULTS: HMWH and LMWH blocked VEGF proliferative actions and blunted VEGF-induced [Ca2+]i transients. However, the heparins did not block the VEGF protective effects on EC. These changes occurred in parallel with a potentiation of the VEGF-related NO production by both heparins. The Akt/PI3K inhibitor, LY 294002, blocked this potentiation, related to increased eNOS activity rather than eNOS expression. Connecting both effects, the NO antagonist, L-NAME, shifted the protective effects of VEGF to a cytotoxic mode. CONCLUSION: HMWH and LMWH block the proliferative and [Ca2+]i-mobilizing effects of VEGF on EC, by a NO-dependent mechanism. On the contrary, VEGF-induced NO production is stimulated. The Akt/PI3K pathway at least in part mediates this effect. By changing the way the VEGF intracellular signaling is driven, heparin could act as a stabilizing factor for the endothelium, without stimulating vessel proliferation.


Subject(s)
Anticoagulants/pharmacology , Endothelium, Vascular/metabolism , Heparin/pharmacology , Nitric Oxide/physiology , Vascular Endothelial Growth Factor A/metabolism , Animals , Aorta/cytology , Blotting, Northern , Cattle , Cell Proliferation/drug effects , Cell Survival/drug effects , Cells, Cultured , Chromones/pharmacology , Endothelium, Vascular/cytology , Endothelium, Vascular/drug effects , Enzyme Inhibitors/pharmacology , Flow Cytometry , In Vitro Techniques , Morpholines/pharmacology , NG-Nitroarginine Methyl Ester/pharmacology , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase/metabolism , Nitric Oxide Synthase Type III , RNA, Messenger/genetics , Vascular Endothelial Growth Factor A/drug effects
14.
Am J Physiol Cell Physiol ; 286(5): C1170-6, 2004 May.
Article in English | MEDLINE | ID: mdl-15075216

ABSTRACT

Proangiogenic, proliferative effects of tumors have been extensively characterized in subconfluent endothelial cells (EC), but results in confluent, contact-inhibited EC are critically lacking. The present study examined the effect of tumor-conditioned medium (CM) of the malignant osteoblastic cell line MG63 on monolayer, quiescent bovine aorta EC. MG63-CM and MG63-CM + CoCl(2) significantly increased EC survival in serum-starved conditions, without inducing EC proliferation. Furthermore, MG63-CM and MG63-CM + CoCl(2), both containing high amounts of vascular endothelial growth factor (VEGF), induced relevant phenotypic changes in EC (all P < 0.01) involving increase of nucleoli/chromatin condensations, nucleus-to-cytosol ratio, capillary-like vacuolated structures, vessel-like acellular areas, migration through Matrigel, growth advantage in reseeding, and factor VIII content. All these actions were significantly inhibited by VEGF and VEGF receptor (VEGFR2) blockade. Of particular importance, a set of similar effects were detected in a human microvascular endothelial cell line (HMEC). With regard to gene expression, incubation with MG63-CM abolished endogenous VEGF mRNA and protein but induced a clear-cut increase in VEGFR2 mRNA expression in EC. In terms of mechanism, MG63-CM activates protein kinase B (PKB)/Akt, p44/p42-mitogen-activated protein kinase (MAPK)-mediated pathways, as suggested by both inhibition and phosphorylation experiments. In conclusion, tumor cells activate confluent, quiescent EC, promoting survival, phenotypic, and gene expression changes. Of importance, VEGF antagonism converts MG63-CM from protective to EC-damaging effects.


Subject(s)
Culture Media, Conditioned/pharmacology , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiology , Neoplasms/metabolism , Protein Serine-Threonine Kinases , Vascular Endothelial Growth Factor A/physiology , Animals , Aorta , Cattle , Cell Line, Tumor/metabolism , Cells, Cultured , Endothelium, Vascular/cytology , Humans , Mitogen-Activated Protein Kinases/metabolism , Phosphorylation/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-akt , RNA, Messenger/metabolism , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor Receptor-2/genetics , Vascular Endothelial Growth Factor Receptor-2/physiology
15.
Mediciego ; 9(supl.2): 15-23, jul. 2003. tab, graf
Article in Spanish | LILACS | ID: lil-351290

ABSTRACT

Se realizó una investigación prospectiva, controlada, aleatoria y abierta con los pacientes que eran portadores de patologías quirúrgicas de la mano. El objetivo general de la investigación fue evaluar la efectividad de la Analgesia Quirúrgica Acupuntural (AQA) en este tipo de afecciones...


Subject(s)
Humans , Acupuncture Analgesia , Hand , Orthopedics
16.
MediCiego ; 9(1): 15-23, jul. 2003. tab, graf
Article in Spanish | CUMED | ID: cum-22465

ABSTRACT

Se realizó una investigación prospectiva, controlada, aleatoria y abierta con los pacientes que eran portadores de patologías quirúrgicas de la mano. El objetivo general de la investigación fue evaluar la efectividad de la Analgesia Quirúrgica Acupuntural (AQA) en este tipo de afecciones... (AU)


Subject(s)
Humans , Hand , Orthopedic Procedures , Acupuncture Analgesia
17.
Am J Physiol Regul Integr Comp Physiol ; 285(3): R674-81, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12775556

ABSTRACT

The study investigated whether the amelioration of endothelial dysfunction by candesartan (2 mg.kg-1.day-1; 10 wk) in spontaneously hypertensive rats (SHR) was associated with modification of hepatic redox system. Systolic arterial pressure (SAP) was higher (P < 0.05) in SHR than in Wistar-Kyoto rats (WKY) and was reduced (P < 0.05) by candesartan in both strains. Acetylcholine (ACh) relaxations were smaller (P < 0.05) and contractions induced by ACh + NG-nitro-l-arginine methyl ester (l-NAME) were greater (P < 0.05) in SHR than in WKY. Treatment with candesartan enhanced (P < 0.05) ACh relaxations in SHR and reduced (P < 0.05) ACh + l-NAME contractions in both strains. Expression of aortic endothelial nitric oxide synthase (eNOS) mRNA was similar in WKY and SHR, and candesartan increased (P < 0.05) it in both strains. Aortic mRNA expression of the subunit p22phox of NAD(P)H oxidase was higher (P < 0.05) in SHR than in WKY. Treatment with candesartan reduced (P < 0.05) p22phox expression only in SHR. Malonyl dialdehyde (MDA) levels were higher (P < 0.05), and the ratio reduced/oxidized glutathione (GSH/GSSG) as well as glutathione peroxidase activity (GPx) were lower (P < 0.05) in liver homogenates from SHR than from WKY. Candesartan reduced (P < 0.05) MDA and increased (P < 0.05) GSH/GSSG ratio without affecting GPx. Vessel, lumen, and media areas were bigger (P < 0.05) in SHR than in WKY. Candesartan treatment reduced (P < 0.05) media area in SHR without affecting vessel or lumen area. The results suggest that hypertension is not only associated with elevation of vascular superoxide anions but with alterations of the hepatic redox system, where ANG II is clearly involved. The results further support the key role of ANG II via AT1 receptors for the functional and structural vascular alterations produced by hypertension.


Subject(s)
Angiotensin Receptor Antagonists , Endothelium, Vascular/metabolism , Hypertension/drug therapy , Liver/metabolism , Membrane Transport Proteins , Angiotensin II/metabolism , Animals , Antihypertensive Agents/pharmacology , Aorta/metabolism , Aorta/pathology , Benzimidazoles/pharmacology , Biphenyl Compounds , Blood Pressure/drug effects , Blood Pressure/physiology , Endothelium, Vascular/pathology , Gene Expression Regulation, Enzymologic/drug effects , Glutathione/metabolism , Glutathione Disulfide/metabolism , Glutathione Peroxidase/metabolism , Glutathione Reductase/metabolism , Hypertension/metabolism , Hypertension/pathology , Liver/drug effects , Malondialdehyde/metabolism , NADPH Dehydrogenase/genetics , NADPH Oxidases , Nitric Oxide/metabolism , Nitric Oxide Synthase/genetics , Nitric Oxide Synthase Type III , Oxidation-Reduction , Oxidative Stress/drug effects , Phosphoproteins/genetics , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Receptor, Angiotensin, Type 1 , Tetrazoles/pharmacology
18.
Transplantation ; 74(11): 1618-24, 2002 Dec 15.
Article in English | MEDLINE | ID: mdl-12490797

ABSTRACT

BACKGROUND: Recent studies have shown that exogenous administration of vascular endothelial growth factor (VEGF) is protective against cyclosporine A (CsA) renal toxicity. No data are available, however, on the possible role of endogenous VEGF. Our objective was to examine whether endogenous VEGF has a significant role in the renal response against CsA toxicity. METHODS: In vivo, we used high-dose (50-150 mg/kg/day) CsA +/- specific goat anti-mouse VEGF blocking monoclonal antibody (alpha-VEGF) in mice. In vitro, we exposed mouse tubular cells (MCT) to CsA +/- alpha-VEGF. RESULTS: alpha-VEGF markedly enhanced CsA renal toxicity, inducing severe tubular damage and increased blood urea nitrogen. In animals treated with CsA + alpha-VEGF, damage progressed to generalized tubular injury (histology) and apoptosis (terminal deoxynucleotide transferase-mediated dUTP nick-end labeling) with associated anemia and reticulocytosis (18 days of treatment). CsA + alpha-VEGF treatments strikingly increased tubular VEGF and Bcl-xL proteins. In vitro, autocrine production of VEGF by MCT was identified by Western blot. Of specific interest, CsA toxicity in MCT increased significantly in the presence of alpha-VEGF. CONCLUSIONS: Endogenous VEGF has a relevant role in the renal tubular defense against CsA toxicity. Blockade of the VEGF effect by alpha-VEGF results in clear-cut intensification of the tubular injury and appearance of regenerative anemia in the CsA + alpha-VEGF-treated animals. The occurrence of both in vivo and in vitro effects of VEGF blockade provides evidence of a direct protective effect of VEGF on the tubular cell.


Subject(s)
Cyclosporine/poisoning , Cytoprotection/physiology , Endothelial Growth Factors/physiology , Immunosuppressive Agents/poisoning , Intercellular Signaling Peptides and Proteins/physiology , Kidney Tubules/drug effects , Kidney Tubules/physiology , Lymphokines/physiology , Acute Disease , Animals , Antibodies, Monoclonal/pharmacology , Blotting, Western , Cells, Cultured , Drug Synergism , Endothelial Growth Factors/immunology , Female , Intercellular Signaling Peptides and Proteins/immunology , Kidney Tubules/pathology , Lymphokines/immunology , Mice , Proto-Oncogene Proteins c-bcl-2/metabolism , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors , bcl-X Protein
19.
Circ Res ; 91(3): 202-9, 2002 Aug 09.
Article in English | MEDLINE | ID: mdl-12169645

ABSTRACT

The relative importance of cyclophilin (CyP) versus calcineurin (Cn)-mediated mechanisms in the effect of cyclosporin A (CsA) on endothelial cells (ECs) is largely unknown. In cultured ECs, CsA was cytotoxic/proapoptotic or cytoprotective/antiapoptotic at high or low concentrations, respectively. CsA analogs (MeVal-4-CsA and MeIle-4-CsA), which bind to CyP but do not inhibit Cn, closely reproduced the CsA effects. Based on our previous data, the role of vascular endothelial growth factor (VEGF) as a mediator of CsA-induced cytoprotection was further analyzed. The actions of CsA and CsA analogs were shifted from a protective to a cell-damaging pattern in the presence of a specific anti-VEGF monoclonal antibody (mAb). This positive interaction was further supported by a transient increase in cytosolic free calcium concentration ([Ca(2+)](i)) by VEGF after pretreatment with either CsA or MeVal-4-CsA and an increase in the expression and synthesis of VEGF receptor 2 (VEGFR2). Of functional importance, blockade of the interaction between VEGF and VEGFR2 by a VEGFR2 mAb abolished the cytoprotective effect of CsA. In addition, preconditioning with low concentrations of CsA or CsA analogs increased both cytoprotection and VEGFR2 mRNA expression when EC were exposed to higher concentrations of CsA. In summary, our results reveal that (1) the biphasic responses to CsA in EC are related to the interaction of CsA with CyP rather than with Cn and (2) VEGF is a critical factor in the cytoprotective effect of CsA, by a mechanism that involves VEGFR2.


Subject(s)
Cyclophilins/physiology , Cyclosporine/pharmacology , Endothelial Growth Factors/physiology , Endothelium, Vascular/drug effects , Lymphokines/physiology , Nuclear Proteins , Signal Transduction , Animals , Calcineurin/physiology , Calcium/metabolism , Cattle , Cells, Cultured , Cyclosporine/toxicity , Cytoprotection , DNA-Binding Proteins/metabolism , Dose-Response Relationship, Drug , Endothelial Growth Factors/genetics , Endothelial Growth Factors/pharmacology , Endothelium, Vascular/metabolism , Kinetics , Lymphokines/genetics , Lymphokines/pharmacology , NFATC Transcription Factors , RNA, Messenger/biosynthesis , Receptor Protein-Tyrosine Kinases/genetics , Receptor Protein-Tyrosine Kinases/physiology , Receptors, Growth Factor/genetics , Receptors, Growth Factor/physiology , Receptors, Vascular Endothelial Growth Factor , Transcription Factors/metabolism , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
20.
Nephrol Dial Transplant ; 17(3): 392-8, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11865083

ABSTRACT

BACKGROUND: Hydrogen peroxide (H2O2) formation is a critical factor in processes involving ischaemia/ reperfusion. However, the precise mechanism by which reactive oxygen species (ROS) induce vascular damage are insufficiently known. Specifically, activation of phospholipase C gamma (PLCgamma) is a probable candidate pathway involved in vascular smooth muscle cells (VSMC) activation by H2O2. METHODS: The activation of human venous VSMC was measured as cytosolic free calcium mobilization, shape change and protein phosphorylation, focusing on the role of tyrosine phosphorylation-activated PLCgamma. RESULTS: The exposure of VSMC to exogenous H2O2 caused a rapid increase in cytosolic free calcium concentration ([Ca2+]i), and induced a significant VSMC shape change. Both effects were dependent on a tyrosine kinase-mediated mechanism, as determined by the blockade of short-term treatment of VSMC with the protein tyrosine kinase inhibitor, genistein. Giving further support to the putative role of phospholipase C (PLC)-dependent pathways, the [Ca2+]i and VSMC shape change response were equally inhibited by the specific PLC blocker, 1-(6-((17-beta-methoxyestra-1,3,5(10)trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U73122). In addition, U73122 had a protective effect against the deleterious action (24 h) of H2O2 on non-confluent VSMC. As a further clarification of the specific pathway involved, the exposure to H2O2 significantly stimulated the tyrosine phosphorylation of PLCgamma with a concentration- and time-profile similar to that of [Ca(2+)](i) mobilization. CONCLUSIONS: The present study reveals that H(2)O(2) activates PLCgamma on VSMC through tyrosine phosphorylation and that this activation has a major role in rapid [Ca(2+)](i) mobilization, shape-changing actions and damage by H(2)O(2) in this type of cells. These findings have direct implications for understanding the mechanisms of the vascular actions of H(2)O(2) and may help to design pharmacologically protective strategies.


Subject(s)
Hydrogen Peroxide/toxicity , Isoenzymes/metabolism , Muscle, Smooth, Vascular/drug effects , Muscle, Smooth, Vascular/metabolism , Type C Phospholipases/metabolism , Calcium/metabolism , Calcium Signaling/drug effects , Cell Size/drug effects , Cells, Cultured , Humans , Hydrogen Peroxide/metabolism , Manganese/metabolism , Muscle, Smooth, Vascular/cytology , Phospholipase C gamma , Phosphorylation , Reactive Oxygen Species/metabolism , Signal Transduction/drug effects , Tyrosine/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...